Spero Therapeutics Inc (SPRO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

675 MASSACHUSETTS AVENUE CAMBRIDGE, MA 02139

Spero Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on identifying, developing, and commercializing novel treatments for MDR bacterial infections. Spero Therapeutics also offers a technology platform that develops drugs to expand the spectrum and potency of existing antibiotics. Spero Therapeutics serves customers worldwide.

Data as of 2020-11-22
Market Cap412.85 Million Shares Outstanding27.197 Million Avg 30-day Volume232.046 Thousand
P/E Ratio-3.6 Dividend Yield EPS-4.27
Price/Sales37.352 Price cash flow ratio Price free cash flow ratio-4.7
Book Value4.88 Price to Tangible Book3.11 Alpha0.07
Short Interest Ratio % Short Interest to Float R-squared0.058966
BETA2.06852 52-week High/Low15.49 / 5.25 Stddev0.428518

Are you looking for this stock instead?

View SEC Filings from SPRO instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 74 78 -5.13% 24 (1.58%) 24 (1.56%) 0.0%
13F shares: 15.65 Million 10.66 Million 46.81% 8.905 Million 4.617 Million 92.88%
% Ownership 60.2618 51.7614 16.42% 34.2886 22.4167 52.96%
New Positions: 12 28 -57.14% 4 9 -55.56%
Increased Positions 30 34 -11.76% 11 12 -8.33%
Closed Positions 15 8 87.5% 4 2 100.0%
Reduced Positions 21 12 75.0% 7 3 133.33%
Total Calls 24.307 Thousand 1.9 Thousand 1179.32% 16 Thousand
Total Puts 58.6 Thousand 300 19433.33% 27.7 Thousand
PUT/CALL Ratio 2.41 0.16 1406.25% 1.73 981.25%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding SPRO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SPRO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

324 Thousand total shares from 9 transactions

Exercise Derivative Conversion (M)

24 Thousand total shares from 5 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

AQUILO CAPITAL MANAGEMENT, LLC

AQUILO CAPITAL, L.P.

  • 10% Owner
4,197,142 2020-11-09 1

MAHADEVIA ANKIT CEO AND PRESIDENT

  • Officer
  • Director
65,817 2020-11-03 7

VINK PATRICK V.J.J.

  • Director
0 2020-10-27 2

DESHPANDE MILIND

  • Director
0 2020-10-27 2

FORMELA JEAN FRANCOIS

  • Director
0 2020-10-27 2

THOMAS FRANK E

  • Director
0 2020-10-27 2

POTTAGE JOHN C JR

  • Director
0 2020-10-27 1

SMITH CYNTHIA

  • Director
0 2020-10-27 1

JACKSON SCOTT THOMAS

  • Director
0 2020-10-27 3

LARKIN CRISTINA CHIEF OPERATING OFFICER

  • Officer
0 2020-02-03 1

MELNICK DAVID A. CHIEF MEDICAL OFFICER

  • Officer
0 2020-02-03 1

KEUTZER TIMOTHY CHIEF DEVELOPMENT OFFICER

  • Officer
0 2020-02-03 2

DIPALMA STEPHEN J. INTERIM CFO

  • Officer
0 2019-11-08 0

PARR THOMAS R JR CHIEF SCIENTIFIC OFFICER

  • Officer
0 2019-01-02 0

SENDEK JOEL CHIEF FINANCIAL OFFICER

  • Officer
0 2019-01-02 0

GLAXOSMITHKLINE PLC

  • 10% Owner
1,934,006 2018-07-17 0

BREUM CASPER

  • Director
0 2018-06-05 0

SOUTHWELL DAVID P

  • Director
0 2018-06-05 0

GOYAL VIKAS

  • Director
1,854,006 2017-11-06 0

GV 2015 GP, L.L.C.

GV 2015, L.P.

ALPHABET INC.

  • 10% Owner
0 2017-11-01 0

LUNDBECKFOND INVEST A/S

  • 10% Owner
0 2017-11-01 0

ATLAS VENTURE FUND IX, L.P.

ATLAS VENTURE ASSOCIATES IX, L.P.

ATLAS VENTURE ASSOCIATES IX, LLC

  • 10% Owner
42,781 2017-11-01 0

HALSE REZA

  • Director
0 2017-11-01 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

AQUILO CAPITAL MANAGEMENT, LLC - > 10% Owner see footnotes

AQUILO CAPITAL, L.P. - > 10% Owner see footnotes

2020-11-10 19:14:26 -0500 2020-11-09 S 125,900 $13.77 d 4,197,142 indirect -1.5593 0.678 0.678 6 -2.9153 3

AQUILO CAPITAL MANAGEMENT, LLC - > 10% Owner see footnotes

AQUILO CAPITAL, L.P. - > 10% Owner see footnotes

2020-11-06 20:48:12 -0500 2020-11-06 S 5,000 $13.77 d 4,323,042 indirect 3.9017 7.0087 7.0087 6 0.0 1

AQUILO CAPITAL MANAGEMENT, LLC - > 10% Owner see footnotes

AQUILO CAPITAL, L.P. - > 10% Owner see footnotes

2020-11-06 20:48:12 -0500 2020-11-05 S 96,600 $13.98 d 4,328,042 indirect 3.9017 7.0087 7.0087 6 0.0 1

AQUILO CAPITAL MANAGEMENT, LLC - > 10% Owner see footnotes

AQUILO CAPITAL, L.P. - > 10% Owner see footnotes

2020-11-06 20:48:12 -0500 2020-11-04 S 72,500 $14.26 d 4,424,642 indirect 3.9017 7.0087 7.0087 6 0.0 1

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-04 S 7,370 $14.43 d 65,817 direct yes 1.1696 4.6784 7.8216 4 0.0 1

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-04 M 7,370 d 494,809 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-04 M 7,370 $5.90 a 73,187 direct yes 1.1696 4.6784 7.8216 4 0.0 1

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-03 M 2,137 d 502,179 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-03 S 2,137 $14.27 d 65,817 direct yes 1.1696 4.6784 7.8216 4 0.0 1

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-11-05 19:00:10 -0500 2020-11-03 M 2,137 $5.90 a 67,954 direct yes 1.1696 4.6784 7.8216 4 0.0 1

SMITH CYNTHIA - Director

2020-10-27 17:35:08 -0400 2020-10-27 A 7,500 a 7,500 direct

POTTAGE JOHN C JR - Director

2020-10-27 17:30:56 -0400 2020-10-27 A 7,500 a 7,500 direct

THOMAS FRANK E - Director

2020-10-27 17:37:15 -0400 2020-10-27 A 7,500 a 7,500 direct

VINK PATRICK V.J.J. - Director

2020-10-27 17:31:16 -0400 2020-10-27 A 7,500 a 7,500 direct

JACKSON SCOTT THOMAS - Director

2020-10-27 17:34:56 -0400 2020-10-27 A 7,500 a 7,500 direct

FORMELA JEAN FRANCOIS - Director

2020-10-27 17:37:45 -0400 2020-10-27 A 7,500 a 7,500 direct

DESHPANDE MILIND - Director

2020-10-27 17:32:36 -0400 2020-10-27 A 7,500 a 7,500 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-27 17:32:27 -0400 2020-10-23 S 20 $14.25 d 65,817 direct yes 1.5873 4.8375 6.9539 5 -0.9826 4

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-27 17:32:27 -0400 2020-10-23 M 20 $5.90 a 65,837 direct yes 1.5873 4.8375 6.9539 5 -0.9826 4

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-27 17:32:27 -0400 2020-10-23 M 20 d 504,316 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-14 M 105 d 504,336 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-14 M 105 $5.90 a 65,922 direct yes 0.3077 7.8462 7.9231 5 -0.4615 4

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-14 S 105 $14.25 d 65,817 direct yes 0.3077 7.8462 7.9231 5 -0.4615 4

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-13 M 14,367 $5.90 a 80,184 direct yes 0.3077 7.8462 7.9231 5 -0.4615 4

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-13 M 14,367 d 504,441 direct

MAHADEVIA ANKIT - Director - Officer CEO AND PRESIDENT

2020-10-15 20:24:39 -0400 2020-10-13 S 14,367 $14.28 d 65,817 direct yes 0.3077 7.8462 7.9231 5 -0.4615 4

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments